ASHP therapeutic position statement on the institutional use of 0.9% sodium chloride injection to maintain patency of peripheral indwelling intermittent infusion devices.
D002406:Catheterization, Peripheral; D002408:Catheters, Indwelling; D004344:Drug Incompatibility; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D012957:Societies, Pharmaceutical; D012965:Sodium Chloride / Q000008:administration & dosage*
D012965:Sodium Chloride; D006493:Heparin